couter

300347.SZHangzhou Tigermed Consulting Co., Ltd

Oct 25, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Sun25Oct

    Q3 2026 earnings on October 25 will gauge the company's progress in converting its robust backlog into high-margin revenue amidst a challenging macroeconomic environment in China.

  • Sun15Nov

    Ongoing US legislative scrutiny regarding Chinese biopharmaceutical service providers threatens Hangzhou Tigermed's overseas revenue, which accounts for nearly half of total sales.

  • Sun24Jan
  • Mon15Feb

    Industry-wide data on biopharmaceutical R&D spending will offer leading indicators for CRO demand, particularly as lower Fed Funds Rates potentially ease biotech funding constraints.

  • Tue30Mar

    The full-year 2026 earnings report on March 30 will define the narrative for the upcoming year, heavily focusing on the success of the company's multi-regional clinical trial (MRCT) strategy.

  • Sun25Apr
  • Tue15Jun

    Potential updates to FDA and EMA guidelines regarding the acceptability of clinical trial data generated solely in China for global drug applications.

  • Sun25Jul
  • Sun24Oct

Past

  • Fri28Aug

    Actual outcome: Bull · $52.80 at outcome

    The stock closed at $52.80, surpassing the bear floor and trending toward the bull target. The earnings release showed a revenue beat and optimistic guidance, which signaled improved demand and operational efficiency. These developments reinforced investor confidence, driving the price higher despite a slight EPS miss.

    Hangzhou Tigermed will report 1H 2026 earnings on August 28, providing crucial visibility into net income margins and overseas clinical trial bookings.